

Supporting Information for

**One-pot Enantioselective Construction of 3,4-Dihydro-2H-1,4-oxazines
Over Ru/Au Relay Catalysis and Its Mechanistic Serendipity**

Dongfeng Yang,[†] Chengyi Wang,[†] Yu Wang, Guohua Liu, Tanyu Cheng, and Rui Liu**

Key Laboratory of Resource Chemistry of Ministry of Education, Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Normal University, No.100 Guilin Rd, Shanghai 200241, P. R. China

CONTENTS


1. EXPERIMENTAL PART	S2
2. DATA OF COMPOUNDS (1-2), AND CHIRAL PRODUCTS (3).....	S4
3. TABLE 1. SCREENING OF REACTION CONDITIONS.....	S9
4. TABLE 2. CONTROL EXPERIMENT FOR THE CYCLIZATION OF 2a	S9
5. PROPOSED MECHANISM FOR THE ATH PROCESS OF 1a.	S10
6. SINGLE CRYSTAL X-RAY STRUCTURE OF 4.....	S23
7. HPLC ANALYSIS OF CHIRAL ALKYNOLS (2), CHIRAL PRODUCTS (3), AND 4	S24
8. THE ¹H-NMR AND ¹³C-NMR SPECTRA OF 1-2, CHIRAL PRODUCTS (3), AND 4	S67

1. Experimental part

1.1 General. All manipulations were carried out under an inert atmosphere using a nitrogen-filled glovebox or Schlenk techniques. Deuterated solvents were purchased commercially and were degassed and stored over activated 4 Å molecular sieves. η^6 -AreneRuTsDPEN complexes, η^5 -Cp*MTsDPEN complexes (TsDPEN = *N*-(*p*-toluenesulfonyl)-1,2-diphenylethylenediamine) were prepared according to the published procedures. All other reagents and catalysts were obtained from commercial sources and used without further purification. The ^1H NMR spectra were performed on a Bruker Avance DPX-400 spectrometer in $\text{CDCl}_3/\text{DMSO}-d_6$ solutions. Chemicals shifts are given in parts per million (δ units) downfield from tetramethylsilane using the residual solvent signal (CHCl_3 , δ 7.26) as an internal standard. ^1H NMR information is given in the following format: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; sept, septet; m, multiplet), coupling constant(s) (J) in Hertz (Hz), the number of protons. The prefix app is occasionally applied when the true signal multiplicity was unresolved and br indicates the signal in question broadened. $^{13}\text{C}\{^1\text{H}\}$ NMR spectra are reported in ppm (δ) relative to residual CHCl_3 (δ 77.36) unless otherwise noted. The enantiomeric excesses (ee) were determined using a Daicel Chiralcel® column OZ-H or OD-H or OJ-H or AD-H or AS-H or OD-3 with the above HPLC setup. The ^1H NMR and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded at 400 MHz and 100 MHz. Mass spectrometry was performed on an LC/MS spectrometer with the electron spray ionization (ESI) technique. High-resolution mass spectra (HRMS) were performed at the Shanghai institute of organic chemistry.

1.2. General procedure for the synthesis of starting materials.

Procedure A. Synthesis of Alkynones¹




In a typical synthesis, to a solution of *N*-(prop-2-yn-1-yl)sulfonamide (8.0 mmol) in acetone (50 mL) was added α -bromo arylketones (9.6 mmol) and K_2CO_3 (1.3 g, 9.6 mmol). The resulting suspension was stirred at room temperature until the completion of the reaction determined by TLC. Then the reaction solution was carefully concentrated under vacuum. The residue was dissolved in water. The aqueous solution was extracted with ethyl ether (3 ×

¹ Shen, K.; Han, X.; Lu, X. *Org. Lett.* **2013**, *15*, 1732-1735.

10.0 mL). The combined ethyl ether extracts were washed with brine twice and then dehydrated with Na₂SO₄. After evaporation of ethyl ether, the residue was purified by silica gel flash column chromatography to afford the desired alkynes.

Procedure B. Synthesis of Alkynes.

4-methyl-N-(2-oxo-2-(thiophen-2-yl)ethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized following by below procedure.



In a typical synthesis, to an ice-cooled solution of NaH (0.32 g, 8 mmol) in THF (50 mL) was slowly added *N*-propargyl-*p*-toluenesulfonamide (1.70 g, 8.0 mmol). The resulting mixture was vigorously stirred for 0.5 h at 0 °C. Then the NaI (0.12 g, 0.8 mmol) and 2-bromo-1-(thiophen-2-yl)ethan-1-one (1.60 g, 8.0 mmol) was added, and the mixture was stirred overnight at room temperature. After completion of the reaction determined by TLC, the saturated NH₄Cl solution (10 mL) was added at 0 °C. The aqueous solution was extracted with ethyl ether (3 × 10.0 mL). The combined ethyl ether extracts were washed with brine twice and then dehydrated with Na₂SO₄. After evaporation of ethyl ether, the residue was purified by silica gel flash column chromatography over silica gel (PE : EA = 6:1) to give **1q** in 53% yield (1.4 g) as white solid.

2. Data of compounds (1-2), and chiral products (3).

1a: 4-Methyl-N-(2-oxo-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.57 g (60%), white solid ; $R_f = 0.3$

(PE/EA 5/1) ; ^1H NMR (400 MHz, CDCl_3) δ 8.03 – 7.88 (m, 2H), 7.86 – 7.66 (m, 2H), 7.65 – 7.56 (m, 1H), 7.55 – 7.41 (m, 2H), 7.40 – 7.26 (m, 2H), 4.81 (s, 2H), 4.29 (d, $J = 2.2$ Hz, 2H), 2.44 (s, 3H), 2.11 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 193.6 (C), 144.1 (C), 136.4 (C), 135.1 (C), 134.2 (CH x 2), 129.9 (CH x 2), 129.1 (CH x 2), 128.3 (CH x 2), 76.9 (C), 74.7 (CH), 51.8 (CH₂), 37.6 (CH₂), 21.9 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for $[\text{C}_{18}\text{H}_{17}\text{NSO}_3]^{+}$: 327.09, found: 327.09.

1b: *N*-(2-(4-fluorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.71 g (62%), white solid ; $R_f = 0.3$

(PE/EA 5/1) ; ^1H NMR (400 MHz, CDCl_3) δ 8.01 – 7.95 (m, 2H), 7.77 – 7.72 (m, 2H), 7.30 (d, $J = 8.2$ Hz, 2H), 7.16 – 7.09 (m, 2H), 4.74 (s, 2H), 4.25 (d, $J = 2.5$ Hz, 2H), 2.41 (s, 3H), 2.11 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 192.2 (C), 166.4 (C, d, $J = 256.2$ Hz), 144.2 (C), 136.25 (C), 131.6 (C, d, $J = 3.5$ Hz), 131.2 (CH x 2, d, $J = 9.2$ Hz), 130.0 (CH x 2), 127.9 (CH x 2), 116.3 (CH x 2, d, $J = 23.3$ Hz), 76.8 (C), 74.9 (CH), 51.83 (CH₂), 37.7 (CH₂), 21.9 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for $[\text{C}_{18}\text{H}_{16}\text{FNSO}_3]^{+}$: 345.08, found: 345.08.


1c: *N*-(2-(3-fluorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.57 g (57%), white solid ; $R_f = 0.3$

(PE/EA 5/1) ; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (dd, $J = 7.9, 3.5$ Hz, 3H), 7.59 (d, $J = 9.3$ Hz, 1H), 7.44 (td, $J = 8.0, 5.4$ Hz, 1H), 7.29 (d, $J = 8.1$ Hz, 3H), 4.74 (s, 2H), 4.24 (d, $J = 2.5$ Hz, 2H), 2.41 (s, 3H), 2.10 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 192.5 (C, d, $J = 2.3$ Hz), 163.1 (C, d, $J = 248.8$ Hz), 144.3 (C), 137.06 (C, d, $J = 6.3$ Hz), 136.2 (C), 130.90 (CH, d, $J = 7.6$ Hz), 130.0 (CH x 2), 127.9 (CH x 2), 124.13 (CH, d, $J = 3.2$ Hz), 121.18 (CH, d, $J = 21.5$ Hz), 115.10 (CH, d, $J = 22.3$ Hz), 76.7 (C), 74.9 (CH), 52.0 (CH₂), 37.7 (CH₂), 21.8 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for $[\text{C}_{18}\text{H}_{16}\text{FNSO}_3]^{+}$: 345.08, found: 345.08


1d: *N*-(2-(2-fluorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.49 g (54%), white solid ; $R_f = 0.3$

(PE/EA 5/1) ; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (td, $J = 7.5, 1.9$ Hz, 1H), 7.78 – 7.74 (m, 2H), 7.60 – 7.55 (m, 1H), 7.33 – 7.29 (m, 2H), 7.25 (d, $J = 1.1$ Hz, 1H), 7.17 (ddd, $J = 11.1, 8.3, 1.0$ Hz, 1H), 4.75 (d, $J = 3.4$ Hz, 2H), 4.31 (d, $J = 2.5$ Hz, 2H), 2.43 (s, 3H), 2.11 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 191.9 (C, d, $J = 5.5$ Hz), 162.3 (C, d, $J = 254.3$ Hz), 144.0 (C), 136.6 (C), 135.8 (CH, d, $J = 9.2$ Hz), 131.1 (CH, d, $J = 2.9$ Hz), 129.9 (CH x 2), 127.8 (CH x 2), 125.1 (CH, d, $J = 3.2$ Hz), 123.3 (C, d, $J = 14.5$ Hz), 116.9 (CH, d, $J = 23.9$ Hz), 76.9 (C), 74.6 (CH), 55.5 (CH₂), 37.8 (CH₂), 21.8 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for $[\text{C}_{18}\text{H}_{16}\text{FNSO}_3]^{+}$: 327.08, found: 327.08.


1e: *N*-(2-(4-chlorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.68 g (58%), white solid ; $R_f = 0.3$



1f: *N*-(2-(3-chlorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.62 g (56%), white solid ; $R_f = 0.3$




1g: *N*-(2-(2-chlorophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.76 g (61%), white solid ; $R_f = 0.3$




1h: *N*-(2-(4-bromophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.78 g (55%), white solid ; $R_f = 0.3$ (PE/EA 5/1); ^1H NMR (400 MHz, CDCl_3) δ 7.84 – 7.80 (m, 2H), 7.77 – 7.73 (m, 2H), 7.64 – 7.60 (m, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 4.73 (s, 2H), 4.24 (d, $J = 2.4$ Hz, 2H), 2.43 (s, 3H), 2.11 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 192.8 (C), 144.3 (C), 136.1 (C), 133.8 (C), 132.5 (CH x 2), 130.0 (CH x 2), 129.9 (CH x 2), 129.5 (C), 128.0 (CH x 2), 76.7 (C), 74.9 (CH), 51.9 (CH₂), 37.7 (CH₂), 21.9 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for $[\text{C}_{18}\text{H}_{16}\text{BrNSO}_3]^+$: 405.00 , found: 405.00 .

1i: *N*-(2-(3-bromophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.65 g (51%), white solid ; $R_f = 0.3$ (PE/EA 5/1) ; ^1H NMR (400 MHz, CDCl_3) δ 8.08 – 8.03 (m, 1H), 7.90 – 7.87 (m, 1H), 7.77 – 7.71 (m, 3H), 7.37 (t, $J = 7.9$ Hz,




1H), 7.32 (d, $J = 8.2$ Hz, 2H), 4.75 (s, 2H), 4.26 (d, $J = 2.3$ Hz, 2H), 2.44 (s, 3H), 2.13 (t, $J = 2.4$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 192.3 (C), 144.1 (C), 136.8 (CH), 136.6 (C), 136.1 (C), 131.1 (CH), 130.6 (CH), 129.9 (CH x 2), 127.8 (CH x 2), 126.8 (CH), 123.3 (C), 76.6 (C), 74.9 (CH), 51.8 (CH₂), 37.6 (CH₂), 21.75 (CH₃). LC/MS (ESI) m/z [M+H]⁺ calculated for $[\text{C}_{18}\text{H}_{16}\text{BrNSO}_3]^+$: 405.00, found: 405.00.


1j: 4-Methyl-N-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.80 g




1k: *N*-(2-(4-cyanophenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.69 g (60%), white solid ; $R_f = 0.3$



1l: 4-Methyl-*N*-(2-oxo-2-(p-tolyl)ethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.61 g (59%), white solid ; $R_f = 0.3$



1m: *N*-(2-(4-methoxyphenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide



(CH x 2), 128.1 (C), 127.9 (CH x 2), 114.3 (CH x 2), 76.9 (C), 74.6 (CH), 55.8 (CH₂), 51.5 (CH₂), 37.6 (CH₃), 21.8 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for [C₁₉H₁₉NSO₄]⁺: 357.10 , found: 357.10.

1n: *N*-(2-(3-methoxyphenyl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.77 g (62%), white solid ; R_f = 0.3 (PE/EA 5/1); ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.74 (m, 2H), 7.52 (dd, J = 7.6, 1.5 Hz, 1H), 7.48 – 7.45 (m, 1H), 7.38 (td, J = 8.0, 3.0 Hz, 1H), 7.31 (d, J = 8.3 Hz, 2H), 7.16 – 7.12 (m, 1H), 4.78 (s, 2H), 4.27 (d, J = 2.6 Hz, 2H), 3.85 (d, J = 3.2 Hz, 3H), 2.43 (d, J = 2.9 Hz, 3H), 2.12 (t, J = 2.5 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 193.5 (C), 160.2 (C), 144.1 (C), 136.4 (C), 136.4 (C), 130.1 (CH), 129.9 (CH x 2), 127.9 (CH x 2), 120.8 (CH), 120.6 (CH), 112.7 (CH), 76.9 (C), 74.8 (CH), 55.8 (CH₂), 51.9 (CH₂), 37.7 (CH₃), 21.8 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for [C₁₉H₁₉NSO₄]⁺: 357.10, found: 357.10.

1o: *N*-(2-([1,1'-biphenyl]-4-yl)-2-oxoethyl)-4-Methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 2.10 g (65%), white solid ; R_f = 0.3 (PE/EA 3/1) ; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 8.3 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 7.0, 1.6 Hz, 2H), 7.51 – 7.46 (m, 2H), 7.44 – 7.39 (m, 1H), 7.33 (d, J = 8.1 Hz, 2H), 4.85 (s, 2H), 4.31 (d, J = 2.5 Hz, 2H), 2.44 (s, 3H), 2.14 (t, J = 2.5 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 193.1 (C), 146.8 (C), 144.1 (C), 139.8 (C), 136.4 (C), 133.7 (C), 129.9 (CH x 2), 129.3 (CH x 2), 128.9 (CH x 2), 128.7 (CH), 127.9 (CH x 2), 127.7 (CH x 2), 127.5 (CH x 2), 76.9 (C), 74.8 (CH), 51.8 (CH₂), 37.7 (CH₂), 21.9 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for [C₂₄H₂₁NSO₃]⁺: 403.12, found: 403.12


1p: 4-Methyl-*N*-(2-(naphthalen-2-yl)-2-oxoethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.75 g (58%), white solid; R_f = 0.3 (PE/EA 3/1) ; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 8.01 – 7.92 (m, 2H), 7.92 – 7.84 (m, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.65 – 7.53 (m, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.95 (s, 2H), 4.33 (d, J = 2.5 Hz, 2H), 2.43 (s, 3H), 2.14 (t, J = 2.5 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 193.1 (C), 146.8 (C), 144.1 (C), 139.8 (C), 136.4 (C), 133.7 (C), 129.9 (CH x 2), 129.3 (CH x 2), 128.9 (CH x 2), 128.7 (CH), 127.9 (CH x 2), 127.7 (CH x 2), 127.5 (CH x 2), 76.9 (C), 74.8 (CH), 51.8 (CH₂), 37.7 (CH₂), 21.8 (CH₃). LC/MS (ESI) m/z [M]⁺ calculated for [C₂₂H₁₉NSO₃]⁺: 377.11 , found: 377.11.

1q: 4-Methyl-*N*-(2-oxo-2-(thiophen-2-yl)ethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure B. Yield: 1.40 g (53%), white solid; R_f = 0.3


(PE/EA 3/1) ; ¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (dd, J = 22.5, 4.4 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.28 (t, J = 4.0 Hz, 1H), 4.74 (s, 2H), 4.17 (d, J = 2.4 Hz, 2H), 3.14 (t, J = 2.4 Hz, 1H), 2.40 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 187.8 (C), 144.5 (C), 141.7 (C), 136.9 (C), 136.6 (CH), 135.0 (CH), 130.7 (CH),

129.9 (CH x 2), 128.3 (CH x 2), 78.0 (C), 77.8 (CH), 53.2 (CH₂), 38.6 (CH₂), 22.0 (CH₃) . LC/MS (ESI) m/z [M+H]⁺ calculated for [C₁₆H₁₅NS₂O₃]⁺: 334.06 , found: 334.06


1r: 4-Fluoro-N-(2-oxo-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.41 g (54%), white solid ; R_f = 0.3




1s: 4-Chloro-N-(2-oxo-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.59 g (58%), white solid ; R_f = 0.3




1t: 4-Bromo-N-(2-oxo-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.75 g (56%), white solid ; R_f = 0.3



1u: 4-Nitro-N-(2-oxo-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide was synthesized according to above procedure A. Yield: 1.43 g (50%), yellow solid ; R_f = 0.3




3. Table 1. Screening of reaction conditions.^a



Entry	Solvent	Yield of 2a (%) ^b	Yield of 2a' (%) ^b
1	CCl ₄	0	trace
2	CH ₃ CN	0	trace
3	acetone	0	30
4	DCM	0	35
5	CHCl ₃	0	38
6	THF	0	0
7	1,4-dioxane	0	60
8	DMF	trace	0
9	DMSO	0	15
10	EA	0	0
11	toulene	0	58
12	DCE	89	0


^aReaction conditions: **1a** (0.30 mmol), catalyst (0.015 mmol), hydrogen sources (1.20 mmol), 2.0 mL of solvent, reaction time (8 h). ^bIsolated yield.

4. Table 2. Control experiment for the cyclization of 2a



^a Reaction conditions: alkynol **2a** (0.30 mmol), Catalyst C (9.3 mg, 0.015 mmol), AuCl(PPh₃) (14.8 mg, 0.030 mmol), AgNTf₂ (11.6 mg, 0.030 mmol), DCE (2.0 mL), 70 °C, 10 h. ^b Yield was determined by crude ¹H NMR.

5. Proposed mechanism for the ATH process of **1a**.




The plausible mechanism for the first ATH process was proposed using **1a** as the model (above Scheme). In the presence of HCOONa, the chloride precatalyst **Ru-1** generally led to the formato complex **Ru-2** which could undergo the decarboxylation process to provide ruthenium hydride **Ru-3**. Then the concerted hydrogen transfer process of **1a** occurs as reported by Noyori (J. Am. Chem. Soc., 2000, 122, 1466-1478; J. Org. Chem., 2001, 66, 7931-7944). Upon reduction of **1a**, the coordination unsaturated **Ru-5** could recombine the HCOONa to restart the catalytic cycle.”

2a: (*R*)-*N*-(2-hydroxy-2-phenylethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (95 mg, 96% yield, 97% ee). $R_f = 0.3$ (PE/EA 3/1). $[\alpha]_D^{25} = +8$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J = 8.3$ Hz, 2H), 7.33 (d, $J = 6.9$ Hz, 2H), 7.28 (t, $J = 7.3$ Hz, 2H), 7.25 – 7.21 (m, 1H), 7.20 (d, $J = 8.4$ Hz, 2H), 4.91 (dd, $J = 8.7, 3.5$ Hz, 1H), 4.18 – 3.99 (m, 2H), 3.37 – 3.22 (m, 2H), 2.33 (s, 3H), 2.00 (t, $J = 2.4$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.2 (C), 141.4 (C), 135.5 (C), 129.9 (CH x 2), 128.8 (CH x 2), 128.3 (CH), 128.0 (CH x 2), 126.2 (CH x 2), 77.1 (C), 74.4 (CH), 72.7 (CH), 54.6 (CH₂), 38.6 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₂₀NSO₃]⁺: 330.1158, found: 330.1158. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 44 min, t_{minor} = 52 min).


2b: (*R*)-*N*-(2-(3-fluorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (97 mg, 93% yield, 94% ee). $R_f = 0.3$ (PE/EA 3/1). $[\alpha]_D^{25} = +10$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, $J = 8.2$ Hz, 2H), 7.36 (dd, $J = 8.0, 5.8$ Hz, 2H), 7.27 (d, $J = 8.7$ Hz, 2H), 7.03 (t, $J = 8.7$ Hz, 2H), 4.97 (dd, $J = 8.6, 3.3$ Hz, 1H), 4.23 – 4.06 (m, 2H), 3.39 – 3.25 (m, 2H), 2.40 (s, 3H), 2.07 (t, $J = 2.3$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 162.7 (C, d, $J = 246.1$ Hz), 144.3 (C), 137.2 (C, d, $J = 2.9$ Hz), 135.6 (C), 129.9 (CH x 2), 128.1 (CH x 2), 127.97 (CH x 2, d, $J = 8.1$ Hz), 115.7 (CH x 2, d, $J = 21.5$ Hz), 77.1 (C), 74.5 (CH), 72.1 (CH), 54.7 (CH₂), 38.7 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSFNaO₃]⁺: 370.0884, found: 370.0884.

HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 31$ min, $t_{\text{minor}} = 42$ min).


2c: (*R*)-*N*-(2-(3-fluorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (96 mg, 92% yield, 96% ee). $R_f = 0.3$ (PE/EA 3/1).


 $[\alpha]_D^{25} = + 6$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, $J = 8.3$ Hz, 2H), 7.34 – 7.26 (m, 3H), 7.15 (t, $J = 9.2$ Hz, 2H), 6.98 (td, $J = 7.9$, 2.0 Hz, 1H), 4.99 (dd, $J = 8.2$, 3.8 Hz, 1H), 4.24 – 4.09 (m, 2H), 3.39 – 3.28 (m, 2H), 2.41 (s, 3H), 2.09 (t, $J = 2.4$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 163.2 (C, d, $J = 246.4$ Hz), 144.3 (C), 144.2 (C, d, $J = 6.9$ Hz), 135.6 (C), 130.38 (CH, d, $J = 8.1$ Hz), 129.9 (CH x 2), 128.0 (CH x 2), 121.8 (CH, d, $J = 2.8$ Hz), 115.1 (CH, d, $J = 21.0$ Hz), 113.2 (CH, d, $J = 22.0$ Hz), 77.0 (C), 74.5 (CH), 72.12 (CH, d, $J = 1.7$ Hz), 54.6 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSFNaO₃]⁺: 370.0884, found: 370.0884. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 36$ min, $t_{\text{minor}} = 41$ min).

2d: (*R*)-*N*-(2-(2-fluorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (92 mg, 88% yield, 85% ee). $R_f = 0.3$ (PE/EA 3/1).


 $[\alpha]_D^{25} = + 23$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.72 (m, 2H), 7.60 (td, $J = 7.5$, 1.7 Hz, 1H), 7.29 – 7.24 (m, 3H), 7.17 (td, $J = 7.5$, 1.1 Hz, 1H), 7.00 (ddd, $J = 10.4$, 8.2, 1.1 Hz, 1H), 5.29 – 5.25 (m, 1H), 4.22 – 4.13 (m, 2H), 3.42 – 3.39 (m, 2H), 2.40 (s, 3H), 2.07 (t, $J = 2.5$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 160.0 (C, d, $J = 245.8$ Hz), 144.3 (C), 135.7 (C), 129.9 (CH x 2), 129.7 (C, d, $J = 8.2$ Hz), 128.4 (CH, d, $J = 13.3$ Hz), 128.2 (CH x 2), 128.0 (CH, d, $J = 4.3$ Hz), 124.8 (CH, d, $J = 3.4$ Hz), 115.6 (CH, d, $J = 21.4$ Hz), 77.0 (C), 74.4 (CH), 66.9 (C, d, $J = 2.0$ Hz), 53.3 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSFNaO₃]⁺: 370.0884, found: 370.0884. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 22$ min, $t_{\text{minor}} = 27$ min).

2e: (*R*)-*N*-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (105 mg, 96% yield, 95% ee). $R_f = 0.3$ (PE/EA 5/1).


 $[\alpha]_D^{25} = + 18$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, $J = 8.2$ Hz, 2H), 7.22 (s, 4H), 7.19 (d, $J = 8.6$ Hz, 2H), 4.88 (dd, $J = 8.4$, 3.6 Hz, 1H), 4.14 – 3.99 (m, 2H), 3.29 – 3.17 (m, 2H), 2.32 (s, 3H), 2.00 (t, $J = 2.3$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.3 (C), 140.0 (C), 135.7 (C), 134.1 (C), 130.0 (CH x 2), 129.0 (CH x 2), 128.1 (CH x 2), 127.7 (CH x 2), 77.1 (C), 74.5 (CH), 72.1 (CH), 54.7 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSClNaO₃]⁺: 386.0558, found: 386.0558. HPLC (Daicel Chiralcel® column OD-3, elute: Hexane/*i*-PrOH = 97/3, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 41$ min, $t_{\text{minor}} = 49$ min).

2f: (*R*)-*N*-(2-(3-chlorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (98 mg, 90% yield, 95% ee). $R_f = 0.3$ (PE/EA 5/1). $[\alpha]_D^{25} = + 4$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz,

CDCl_3) δ 7.71 (d, $J = 8.3$ Hz, 2H), 7.40 (s, 1H), 7.33 – 7.22 (m, 5H), 4.97 (dd, $J = 8.5, 3.6$ Hz, 1H), 4.26 – 4.09 (m, 2H), 3.38 – 3.27 (m, 2H), 2.41 (s, 3H), 2.09 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.3 (C), 143.6 (C), 135.6 (C), 134.8 (C), 130.1 (CH), 129.9 (CH x 2), 128.4 (CH), 128.0 (CH x 2), 126.4 (CH), 124.5 (CH), 77.0 (C), 74.6 (CH), 72.1 (CH), 54.6 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSClNaO₃]⁺: 386.0558, found: 386.0558. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, t_{major} = 43 min, t_{minor} = 50 min).

2g: (R)-N-(2-(2-chlorophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (101 mg, 93% yield, 81% ee). R_f = 0.3 (PE/EA 5/1). $[\alpha]_D^{25} = + 22$ ($c = 0.1$, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, $J = 8.3$ Hz, 2H), 7.71 (d, $J = 7.9$ Hz, 1H), 7.30 (dd, $J = 14.2, 7.9$ Hz, 4H), 7.25 – 7.21 (m, 1H), 5.34 (dd, $J = 8.6, 2.4$ Hz, 1H), 4.25 – 4.17 (m, 2H), 3.49 – 3.29 (m, 2H), 2.41 (s, 3H), 2.05 (t, $J = 2.4$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.3 (C), 138.6 (C), 135.8 (C), 132.0 (C), 129.9 (CH x 2), 129.7 (CH), 129.4 (CH), 128.2 (CH x 2), 128.1 (CH), 127.6 (CH), 77.2 (C), 74.4 (CH), 69.1 (CH), 52.9 (CH₂), 38.7 (CH₂), 21.9 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSClNaO₃]⁺: 386.0558, found: 386.0558. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 25 min, t_{minor} = 33 min).


2h: (R)-N-(2-(4-bromophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (116 mg, 95% yield, 95% ee). R_f = 0.3 (PE/EA 5/1). $[\alpha]_D^{25} = + 12$ ($c = 0.1$, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, $J = 8.3$ Hz, 2H), 7.47 – 7.43 (m, 2H), 7.27 (d, $J = 2.7$ Hz, 2H), 7.26 – 7.24 (m, 2H), 4.94 (dd, $J = 8.4, 3.6$ Hz, 1H), 4.21 – 4.05 (m, 2H), 3.36 – 3.23 (m, 2H), 2.39 (s, 3H), 2.06 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.3 (C), 140.5 (C), 135.6 (C), 132.0 (CH x 2), 130.0 (CH x 2), 128.1 (CH x 2), 128.0 (CH x 2), 122.1 (C), 77.1 (C), 74.5 (CH), 72.2 (CH), 54.6 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₈H₁₈NSBrNaO₃]⁺: 430.0083, found: 430.0083. HPLC (Daicel Chiralcel® column OD-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 26 min, t_{minor} = 30 min).

2i: (R)-N-(2-(3-bromophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide.

A colorless oil (114 mg, 93% yield, 94% ee). R_f = 0.3 (PE/EA 5/1). $[\alpha]_D^{25} = + 5$ ($c = 0.1$, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.74 – 7.70 (m, 2H), 7.55 (t, $J = 1.7$ Hz, 1H), 7.44 – 7.39 (m, 1H), 7.30 (dd, $J = 12.2, 7.9$ Hz, 3H), 7.21 (t, $J = 7.8$ Hz, 1H), 4.96 (dd, $J = 8.5, 3.6$ Hz, 1H), 4.26 – 4.10 (m, 2H), 3.38 – 3.26 (m, 2H), 2.41 (s, 3H), 2.10 (t, $J = 2.5$ Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.3 (C), 143.8 (C), 135.6 (C), 131.4 (CH), 130.4 (CH), 130.0 (CH x 2), 129.3 (CH), 128.1 (CH x 2), 124.9 (CH), 123.0 (C), 77.0 (C), 74.6 (CH), 72.1 (CH), 54.7 (CH₂), 38.8 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for

$[C_{18}H_{18}NSBrNaO_3]^+$: 430.0083, found: 430.0083. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, $t_{\text{major}} = 45$ min, $t_{\text{minor}} = 53$ min).

2j: (*R*)-*N*-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (107 mg, 90% yield, 94% ee). $R_f = 0.3$ (PE/EA 1/1).



$[\alpha]_D^{25} = +12$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, $J = 8.3$ Hz, 2H), 7.59 (d, $J = 8.2$ Hz, 2H), 7.51 (d, $J = 8.2$ Hz, 2H), 7.27 (d, $J = 8.7$ Hz, 2H), 5.06 (dd, $J = 8.3, 3.6$ Hz, 1H), 4.24 – 4.10 (m, 2H), 3.39 – 3.29 (m, 2H), 2.40 (s, 3H), 2.09 (t, $J = 2.4$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 145.4 (C), 144.4 (C), 135.4 (C), 130.4 (C, d, $J = 31.9$ Hz), 130.0 (CH x 2), 128.0 (CH x 2), 126.6 (CH x 2), 125.8 (CH x 2, q, $J = 3.9$ Hz), 124.4 (C, d, $J = 272.1$ Hz), 76.9 (C), 74.6 (CH), 72.2 (CH), 54.6 (CH₂), 38.9 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₉H₁₈NSNaF₃O₃]⁺: 420.0851, found: 420.0851. HPLC (Daicel Chiralcel® column OD-3, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 21$ min, $t_{\text{minor}} = 26$ min).


2k: (*R*)-*N*-(2-(4-cyanophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (98 mg, 92% yield, 92% ee). $R_f = 0.3$ (PE/EA 1/1). $[\alpha]_D^{25} = +11$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ

7.70 (d, $J = 6.6$ Hz, 2H), 7.64 (d, $J = 6.3$ Hz, 2H), 7.53 (d, $J = 7.4$ Hz, 2H), 7.29 (d, $J = 7.9$ Hz, 2H), 5.06 (dd, $J = 7.5, 4.4$ Hz, 1H), 4.21 – 4.10 (m, 2H), 3.37 – 3.29 (m, 2H), 2.41 (s, 3H), 2.10 (t, $J = 2.1$ Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 146.8 (C), 144.5 (C), 135.4 (C), 132.7 (CH x 2), 130.0 (CH x 2), 128.01 (CH x 2), 127.1 (CH x 2), 118.9 (C), 112.0 (C), 76.9 (C), 74.7 (CH), 72.2 (CH), 54.5 (CH₂), 39.0 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₉H₁₈SNaN₂O₃]⁺: 377.0930, found: 377.0930. HPLC (Daicel Chiralcel® column OD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 25$ min, $t_{\text{minor}} = 30$ min).

2l: (*R*)-*N*-(2-hydroxy-2-(p-tolyl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (99 mg, 96% yield, 96% ee). $R_f = 0.3$ (PE/EA 5/1). $[\alpha]_D^{25} = +25$ ($c = 1.0$,

CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J = 8.1$ Hz, 2H), 7.20 (t, $J = 8.0$ Hz, 4H), 7.09 (d, $J = 7.6$ Hz, 2H), 4.87 (dd, $J = 8.6, 3.1$ Hz, 1H), 4.18 – 3.99 (m, 2H), 3.35 – 3.19 (m, 2H), 2.33 (s, 3H), 2.27 (s, 3H), 2.00 – 1.95 (t, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 144.2 (C), 138.5 (C), 138.1 (C), 135.9 (C), 129.9 (CH x 2), 129.6 (CH x 2), 128.1 (CH x 2), 126.2 (CH x 2), 77.3 (C), 74.3 (CH), 72.6 (CH), 54.7 (CH₂), 38.7 (CH₂), 21.8 (CH₃), 21.5 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₉H₂₁NSNaO₃]⁺: 366.1134, found: 366.1134. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/i-PrOH = 98/2, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 123$ min, $t_{\text{minor}} = 140$ min).


2m: (*R*)-*N*-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (105 mg, 97% yield, 98% ee). $R_f = 0.3$ (PE/EA 4/1).




$[\alpha]_D^{25} = +27$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J = 8.2$ Hz, 2H), 7.24 (d, $J = 8.5$ Hz, 2H), 7.20 (d, $J = 7.9$ Hz, 2H), 6.81 (d, $J = 8.6$ Hz, 2H), 4.86 (dd, $J = 8.7, 3.5$ Hz, 1H), 4.18 – 3.98 (m, 2H), 3.72 (s,

3H), 3.35 – 3.18 (m, 2H), 2.33 (s, 3H), 1.99 (t, J = 2.2 Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 159.7 (C), 144.2 (C), 135.8 (C), 133.5 (C), 129.9 (CH x 2), 128.1 (CH x 2), 127.5 (CH x 2), 114.3 (CH x 2), 77.2 (C), 74.3 (CH), 72.3 (CH), 55.6 (CH₂), 54.6 (CH₂), 38.6 (CH₃), 21.9 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₉H₂₁NSNaO₄]⁺: 382.1083, found: 382.1083. HPLC (Daicel Chiralcel® column AS-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 43 min, t_{minor} = 46 min).

2n: (*R*)-*N*-(2-hydroxy-2-(3-methoxyphenyl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (98 mg, 91% yield, 95% ee). R_f = 0.3 (PE/EA 5/1).

 [math]\alpha\text{D}^{25} = +3 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.75 – 7.70 (m, 2H), 7.26 (t, J = 7.9 Hz, 3H), 6.96 (d, J = 8.5 Hz, 2H), 6.86 – 6.80 (m, 1H), 4.96 (dd, J = 8.6, 3.5 Hz, 1H), 4.25 – 4.08 (m, 2H), 3.81 (s, 3H), 3.43 – 3.29 (m, 2H), 2.41 (s, 3H), 2.07 (t, J = 2.4 Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 160.2 (C), 144.2 (C), 143.2 (C), 135.9 (C), 129.9 (CH), 129.9 (CH x 2), 128.1 (CH x 2), 118.5 (CH), 113.9 (CH), 111.72 (CH), 77.2 (C), 74.4 (CH), 72.7 (CH), 55.6 (CH₃), 54.6 (CH₂), 38.7 (CH₂), 21.8 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₉H₂₁NSNaO₄]⁺: 382.1083, found: 382.1083. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, t_{major} = 28 min, t_{minor} = 35 min).


2o: (*R*)-*N*-(2-([1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (113 mg, 93% yield, 95% ee). R_f = 0.3 (PE/EA 4/1).

 [math]\alpha\text{D}^{25} = +15 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, J = 8.4 Hz, 2H), 7.62 – 7.57 (m, 4H), 7.50 – 7.42 (m, 4H), 7.38 – 7.33 (m, 1H), 7.28 (d, J = 8.0 Hz, 2H), 5.06 (dd, J = 8.7, 3.5 Hz, 1H), 4.30 – 4.12 (m, 2H), 3.49 – 3.35 (m, 2H), 2.41 (s, 3H), 2.09 (t, J = 2.4 Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.2 (C), 141.3 (C), 141.0 (C), 140.5 (C), 135.8 (C), 129.9 (CH x 2), 129.1 (CH x 2), 128.1 (CH x 2), 127.7 (CH), 127.6 (CH x 2), 127.4 (CH x 2), 126.7 (CH x 2), 77.2 (C), 74.4 (CH), 72.6 (CH), 54.7 (CH₂), 38.8 (CH₂), 21.9 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₂₄H₂₃NSNaO₃]⁺: 428.1291, found: 428.1291. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 31 min, t_{minor} = 37 min).

2p: (*R*)-*N*-(2-hydroxy-2-(naphthalen-2-yl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (108 mg, 95% yield, 96% ee). R_f = 0.3 (PE/EA 4/1). [math]\alpha\text{D}^{25} = +6 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (s, 1H), 7.86 – 7.81 (m, 3H), 7.73 (d, J = 8.3 Hz, 2H), 7.52 – 7.46 (m, 3H), 7.25 (d, J = 8.1 Hz, 2H), 5.16 (dd, J = 8.4, 3.6 Hz, 1H), 4.27 – 4.10 (m, 2H), 3.53 – 3.39 (m, 2H), 2.39 (s, 3H), 2.09 (t, J = 2.4 Hz, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.19 (C), 138.86 (C), 135.81 (C), 133.60 (C), 133.47 (C), 129.89 (CH x 2), 128.70 (CH), 128.34 (CH), 128.09 (CH x 2), 128.01 (CH), 126.60 (CH), 126.39 (CH), 125.27 (CH), 124.11 (CH), 77.24 (C), 74.41 (CH), 72.93 (CH), 54.65 (CH₂), 38.79 (CH₂), 21.82 (CH₃). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₂₂H₂₁NSNaO₃]⁺: 402.1134, found: 402.1134. HPLC (Daicel Chiralcel® column AD-H,


elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, *t_{major}* = 34 min, *t_{minor}* = 40 min).

2q: (*S*)-*N*-(2-hydroxy-2-(thiophen-2-yl)ethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (92 mg, 91% yield, 98% ee). *R_f* = 0.3 (PE/EA 3/1).




HPLC (Daicel Chiralcel® column OB-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, *t_{major}* = 33 min, *t_{minor}* = 45 min).


2r: (*R*)-4-Fluoro-*N*-(2-hydroxy-2-phenylethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (94 mg, 94% yield, 94% ee). *R_f* = 0.3 (PE/EA 3/1). $[\alpha]_D^{25} = -24$ ($c = 0.1$,




2s: (*R*)-4-Chloro-*N*-(2-hydroxy-2-phenylethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A





2t: (*R*)-4-Bromo-*N*-(2-hydroxy-2-phenylethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A colorless oil (106 mg, 90% yield, 94% ee). *R_f* = 0.3 (PE/EA 3:1). $[\alpha]_D^{25} = -10$ ($c = 0.1$,




(C), 126.2 (CH x 2), 76.8 (C), 74.7 (CH), 72.9 (CH), 54.4 (CH₂), 38.6 (CH₂). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₇H₁₆NSBrNaO₃]⁺: 415.9926, found: 415.9926. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 21 °C, t_{major} = 24 min, t_{minor} = 40 min).

2u: (*R*)-*N*-(2-hydroxy-2-phenylethyl)-4-nitro-*N*-(prop-2-yn-1-yl)benzenesulfonamide. A yellow oil (94 mg, 87% yield, 97% ee). R_f = 0.3 (PE/EA 2/1).  [α]_D²⁵ = -53 (c = 0.1, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 8.37 – 8.24 (m, 2H), 8.08 – 7.94 (m, 2H), 7.42 – 7.35 (m, 4H), 7.35 – 7.28 (m, 1H), 5.02 (dd, J = 8.5, 3.8 Hz, 1H), 4.36 – 4.13 (m, 2H), 3.49 – 3.35 (m, 2H), 2.06 (t, J = 2.5 Hz, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 150.6 (C), 144.9 (C), 141.2 (C), 129.4 (CH x 2), 129.1 (CH x 2), 128.7 (CH), 126.2 (CH x 2), 124.5 (CH x 2), 76.6 (C), 74.9 (CH), 73.4 (CH), 54.4 (CH₂), 38.8 (CH₂). HRMS (ESI) m/z [M+Na]⁺ calculated for [C₁₇H₁₆SNaN₂O₅]⁺: 383.0672 found: 383.0672. HPLC (Daicel Chiralcel® column AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 39 min, t_{minor} = 43 min).

3a: (*R*)-6-Methyl-2-phenyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (64.2 mg, 65% yield, 96% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = +102 (c = 0.1, CHCl₃) ;  ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.79 – 7.74 (m, 2H), 7.54 (d, J = 7.7 Hz, 2H), 7.43 – 7.36 (m, 3H), 7.24 – 7.20 (m, 2H), 6.01 (t, J = 1.2 Hz, 1H), 4.03 (dd, J = 9.2, 2.3 Hz, 1H), 3.85 (ddd, J = 13.6, 2.4, 1.4 Hz, 1H), 3.06 (dd, J = 13.5, 9.2 Hz, 1H), 2.46 (s, 3H), 1.82 (d, J = 1.0 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 145.1 (C), 141.3 (C), 137.9 (C), 133.8 (C), 131.0 (CH x 2), 129.4 (CH x 2), 129.3 (CH), 128.2 (CH x 2), 127.0 (CH x 2), 100.6 (CH), 74.0 (CH), 48.9 (CH₂), 21.9 (CH₃), 18.3 (CH₃). HRMS (ESI-MS) m/z [M+H]⁺ calculated for [C₁₈H₂₀NSO₃]⁺: 330.1158, found: 330.1158. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 15 min, t_{minor} = 23 min).

3b: (*R*)-2-(4-fluorophenyl)-6-Methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (62.5 mg, 60% yield, 94% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = +75 (c = 0.1, CHCl₃) ;  ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76 (d, J = 8.2 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 7.33 – 7.18 (m, 4H), 6.01 (s, 1H), 4.11 (dd, J = 9.1, 2.3 Hz, 1H), 3.85 (dt, J = 13.3, 1.8 Hz, 1H), 3.07 (dd, J = 13.5, 9.1 Hz, 1H), 2.46 (s, 3H), 1.81 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 163.2 (d, J = 244.5 Hz), 145.3 (C), 141.4 (C), 134.5 (d, J = 2.9 Hz), 134.1 (C), 131.2 (CH x 2), 129.5 (CH x 2, d, J = 8.4 Hz), 128.5 (CH x 2), 116.5 (CH x 2, d, J = 21.4 Hz), 100.9 (CH), 73.7 (CH), 49.0 (CH₂), 22.2 (CH₃), 18.5 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉FNSO₃]⁺: 348.1064, found: 348.1063. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 16 min, t_{minor} = 26 min).

3c: (*R*)-2-(3-fluorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (66.7 mg, 64% yield, 95% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = +23 (c = 0.1, CHCl₃) ;  ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76 (d, J = 6.9 Hz, 2H), 7.52 (d, J = 7.3 Hz, 2H), 7.47 – 7.42 (m, 1H), 7.21 (t, J = 8.6 Hz, 1H), 7.10 (d, J = 8.3 Hz, 2H), 6.01 (s, 1H), 4.16 (d, J = 8.7 Hz, 1H), 3.87 (d, J = 13.4 Hz, 1H), 3.09 (dd,

$J = 13.2, 9.1$ Hz, 1H), 2.46 (d, $J = 2.5$ Hz, 3H), 1.82 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 163.1 (C, d, $J = 244.0$ Hz), 145.1 (C), 140.9 (C), 140.8 (C, d, $J = 7.5$ Hz), 133.9 (C), 131.5 (CH, d, $J = 8.4$ Hz), 131.0 (CH x 2), 128.3 (CH x 2), 123.2 (CH), 116.2 (CH, d, $J = 21.1$ Hz), 114.0 (CH, d, $J = 22.5$ Hz), 100.8 (CH), 73.5 (d, $J = 2.0$ Hz), 48.6 (CH₂), 22.0 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉FNSO₃]⁺: 348.1064, found: 348.1064. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 12 min, t_{minor} = 17 min).

3d: (R)-2-(2-fluorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil (63.6 mg, 61% yield, 85% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = + 20 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, DMSO- d_6) δ 7.76 – 7.70 (m, 2H), 7.51 (d, $J = 7.6$ Hz, 2H), 7.47 – 7.41 (m, 1H), 7.35 (td, $J = 7.5, 1.8$ Hz, 1H), 7.29 – 7.22 (m, 2H), 6.04 (s, 1H), 4.23 (dd, $J = 9.2, 2.3$ Hz, 1H), 3.92 (ddd, $J = 13.8, 2.3, 1.4$ Hz, 1H), 3.15 (dd, $J = 13.8, 9.2$ Hz, 1H), 2.45 (s, 3H), 1.84 (d, $J = 1.1$ Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 159.9 (C, d, $J = 246.0$ Hz), 145.0 (C), 141.4 (C), 133.9 (C), 131.4 (CH, d, $J = 8.3$ Hz), 131.0 (CH x 2), 128.8 (CH, d, $J = 3.4$ Hz), 128.2 (CH x 2), 125.7 (CH, d, $J = 3.3$ Hz), 124.8 (C, d, $J = 12.8$ Hz), 116.3 (CH, d, $J = 21.0$ Hz), 100.6 (CH), 68.3 (CH, d, $J = 3.5$ Hz), 47.6 (CH₂), 21.9 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉FNSO₃]⁺: 348.1064, found: 348.1063. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 28 min, t_{minor} = 37 min).

3e: (R)-2-(4-chlorophenyl)-6-Methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil (67.7 mg, 62% yield, 98% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = + 58 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, DMSO- d_6) δ 7.77 – 7.73 (m, 2H), 7.51 (d, $J = 7.8$ Hz, 2H), 7.47 – 7.43 (m, 2H), 7.29 – 7.24 (m, 2H), 6.01 (s, 1H), 4.16 (dd, $J = 8.9, 2.3$ Hz, 1H), 3.85 (ddd, $J = 13.4, 2.5, 1.3$ Hz, 1H), 3.08 (dd, $J = 13.4, 8.9$ Hz, 1H), 2.45 (s, 3H), 1.82 (d, $J = 1.1$ Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 145.0 (C), 140.9 (C), 137.0 (C), 133.9 (C), 131.0 (CHx2), 129.4 (CH x 2), 128.9 (CH x 2), 128.2 (CH x 2), 100.7 (CH), 73.5 (CH), 48.6 (CH₂), 22.0 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉ClNSO₃]⁺: 364.0769, found: 364.0769. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 11 min, t_{minor} = 22 min).

3f: (R)-2-(3-chlorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil (61.1 mg, 56% yield, 97% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = + 130 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, DMSO- d_6) δ 7.76 (d, $J = 8.3$ Hz, 2H), 7.51 (d, $J = 8.1$ Hz, 2H), 7.43 (dd, $J = 4.9, 1.5$ Hz, 2H), 7.32 (s, 1H), 7.24 – 7.18 (m, 1H), 6.02 (s, 1H), 4.20 (dd, $J = 8.9, 2.4$ Hz, 1H), 3.88 (d, $J = 12.5$ Hz, 1H), 3.10 (dd, $J = 13.4, 8.8$ Hz, 1H), 2.45 (s, 3H), 1.83 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 145.0 (C), 140.7 (C), 140.4 (C), 134.1 (C), 133.9 (C), 131.3 (CH), 131.0 (CH x 2), 129.3 (CH), 128.2 (CH x 2), 126.9 (CH), 125.8 (CH), 100.8 (CH), 73.5 (CH), 48.5 (CH₂), 22.0 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉ClNSO₃]⁺: 364.0769, found: 364.0768. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 10 min, t_{minor} = 13 min).

3g: (*R*)-2-(2-chlorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil

(57.8 mg, 53% yield, 79% ee). $R_f = 0.3$ (PE/TBME 8/1). $[\alpha]_D^{25} = +42$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.80 – 7.70 (m, 2H), 7.53 – 7.44 (m, 3H), 7.40 (d, $J = 2.8$ Hz, 3H), 6.10 (s, 1H), 4.39 (dd, $J = 9.2, 2.4$ Hz, 1H), 3.94 (qd, $J = 13.8, 2.5, 1.4$ Hz, 1H), 3.05 (dd, $J = 13.9, 9.2$ Hz, 1H), 2.44 (s, 3H), 1.86 (d, $J = 1.0$ Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 144.9 (C), 141.2 (C), 135.1 (C), 134.3 (C), 131.7 (C), 131.0 (CH), 130.9 (CH x 2), 130.2 (CH), 129.0 (CH), 128.6 (CH), 128.3 (CH x 2), 100.6 (CH), 70.9 (CH), 47.2 (CH₂), 21.9 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉ClN₂S₂O₃]⁺: 364.0769, found: 364.0768. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 9 min, t_{minor} = 13 min).

3h: (*R*)-2-(4-bromophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil

(74.7 mg, 61% yield, 93% ee). $R_f = 0.3$ (PE/TBME 8/1). $[\alpha]_D^{25} = +172$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.74 (d, $J = 8.2$ Hz, 2H), 7.60 (s, 2H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.20 (d, $J = 8.4$ Hz, 2H), 6.01 (s, 1H), 4.15 (dd, $J = 8.9, 2.3$ Hz, 1H), 3.84 (d, $J = 13.1$ Hz, 1H), 3.07 (dd, $J = 13.4, 8.8$ Hz, 1H), 2.46 (s, 3H), 1.82 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 145.1 (C), 141.0 (C), 137.4 (C), 133.9 (C), 132.4 (CH x 2), 131.0 (CH x 2), 129.2 (CH x 2), 128.2 (CH x 2), 122.6 (C), 100.8 (CH), 73.6 (CH), 48.6 (CH₂), 22.0 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉ClNSO₃]⁺: 408.0264, found: 408.0263. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 13 min, t_{minor} = 25 min).

3i: (*R*)-2-(3-bromophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. A colorless oil

(73.5 mg, 60% yield, 98% ee). $R_f = 0.3$ (PE/TBME 8/1). $[\alpha]_D^{25} = +167$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76 (d, $J = 8.2$ Hz, 2H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.46 (s, 1H), 7.36 (t, $J = 7.8$ Hz, 1H), 7.25 (d, $J = 7.8$ Hz, 1H), 6.02 (s, 1H), 4.20 (dd, $J = 8.9, 2.3$ Hz, 1H), 3.88 (d, $J = 12.5$ Hz, 1H), 3.10 (dd, $J = 13.4, 8.8$ Hz, 1H), 2.45 (s, 3H), 1.82 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 145.0 (C), 140.7 (C), 140.6 (C), 133.9 (C), 132.2 (CH), 131.6 (CH), 130.9 (CH x 2), 129.7 (CH), 128.2 (CH x 2), 126.2 (CH), 122.7 (C), 100.8 (CH), 73.5 (CH), 48.5 (CH₂), 21.9 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₈H₁₉ClNSO₃]⁺: 408.0264, found: 408.0263. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 21 min, t_{minor} = 26 min).

3j: (*R*)-6-Methyl-4-tosyl-2-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-1,4-oxazine. A

colorless oil (79.9 mg, 67% yield, 91% ee). $R_f = 0.3$ (PE/TBME 4/1). $[\alpha]_D^{25} = +89$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.75 (d, $J = 8.3$ Hz, 4H), 7.49 (t, $J = 8.2$ Hz, 4H), 6.04 (s, 1H), 4.30 (dd, $J = 8.6, 2.3$ Hz, 1H), 3.89 (ddd, $J = 13.4, 2.5, 1.3$ Hz, 1H), 3.12 (dd, $J = 13.4, 8.7$ Hz, 1H), 2.44 (s, 3H), 1.84 (d, $J = 1.1$ Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 145.0 (C), 142.6 (C), 140.6 (C), 133.9 (C), 131.0 (CH x 2), 129.8 (C, d, $J = 31.7$ Hz), 128.2 (CH x 2), 127.9 (CH x 2), 126.3 (CH x 2, q, $J = 3.9$ Hz), 124.9 (C, q, $J = 271.8$ Hz), 100.9 (CH), 73.6 (CH), 48.5





(CH₂), 21.9 (CH₃), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₉H₁₉NSO₃F₃]⁺: 398.1032, found: 398.1031. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 12 min, t_{minor} = 17 min).

3k: (*R*)-4-(6-methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazin-2-yl)benzonitrile. A colorless oil (74.4 mg, 70% yield, 96% ee). R_f = 0.3 (PE/TBME 4/1). [α]_D²⁵ = + 49 (c = 0.1, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.88 – 7.81 (m, 2H), 7.73 (d, *J* = 8.3 Hz, 2H), 7.49 (d, *J* = 8.1 Hz, 2H), 7.47 – 7.42 (m, 2H), 6.03 (s, 1H), 4.35 (dd, *J* = 8.3, 2.4 Hz, 1H), 3.86 (dd, *J* = 13.5, 1.4 Hz, 1H), 3.15 (dd, *J* = 13.4, 8.3 Hz, 1H), 2.44 (s, 3H), 1.83 (d, *J* = 1.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 144.8 (C), 143.1 (C), 140.2 (C), 133.8 (C), 133.1 (CH x 2), 130.7 (CH x 2), 127.9 (CH x 2), 127.7 (CH x 2), 119.2 (C), 111.8 (C), 100.8 (CH), 73.4 (CH), 48.1 (CH₂), 21.7 (CH₃), 18.0 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₉H₁₉SN₂O₃]⁺: 355.1111, found: 355.1110. HPLC (Daicel Chiralcel® column OD-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 19 min, t_{minor} = 25 min).

3l: (*R*)-6-Methyl-2-(p-tolyl)-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (71.1 mg, 69% yield, 97% ee). R_f = 0.3 (PE/TBME 8/1). [α]_D²⁵ = + 21 (c = 0.1, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.77 – 7.73 (m, 2H), 7.53 (dd, *J* = 8.5, 0.8 Hz, 2H), 7.20 (d, *J* = 7.6 Hz, 2H), 7.10 (d, *J* = 8.1 Hz, 2H), 5.99 (t, *J* = 1.2 Hz, 1H), 3.98 (dd, *J* = 9.2, 2.3 Hz, 1H), 3.80 (ddd, *J* = 13.5, 2.4, 1.4 Hz, 1H), 3.03 (dd, *J* = 13.6, 9.2 Hz, 1H), 2.46 (s, 3H), 2.32 (s, 3H), 1.81 (d, *J* = 1.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 145.0 (C), 141.3 (C), 138.7 (C), 135.0 (C), 133.8 (C), 130.9 (CH x 2), 129.9 (CH x 2), 128.2 (CH x 2), 126.9 (CH x 2), 100.5 (CH), 73.9 (CH), 48.9 (CH₂), 21.9 (CH₃), 21.6 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₉H₂₂NSO₃]⁺: 344.1315, found: 344.1315. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 17 min, t_{minor} = 25 min).

3m: (*R*)-2-(4-methoxyphenyl)-6-methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (73.3 mg, 68% yield, 96% ee). R_f = 0.3 (PE/TBME 4/1). [α]_D²⁵ = + 90 (c = 0.1, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.74 (d, *J* = 8.3 Hz, 2H), 7.53 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 8.6 Hz, 2H), 6.94 (d, *J* = 8.6 Hz, 2H), 5.98 (s, 1H), 3.96 (dd, *J* = 9.3, 2.3 Hz, 1H), 3.80 (d, *J* = 2.1 Hz, 1H), 3.77 (s, 3H), 3.04 (dd, *J* = 13.5, 9.3 Hz, 1H), 2.46 (s, 3H), 1.80 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 160.3 (C), 145.1 (C), 141.5 (C), 133.8 (C), 131.0 (CH x 2), 130.0 (C), 128.5 (CH x 2), 128.3 (CH x 2), 114.9 (CH x 2), 100.5 (CH), 73.8 (CH), 56.0 (CH₂), 49.0 (CH₃), 22.0 (CH₃), 18.4 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₉H₂₂NSO₄]⁺: 360.1264, found: 360.1262. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 14 min, t_{minor} = 30 min).

3n: (*R*)-2-(3-methoxyphenyl)-6-methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (63.6 mg, 59% yield, 95% ee). R_f = 0.3 (PE/TBME 6/1). [α]_D²⁵ = + 98 (c = 0.1, CHCl₃) ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.79 – 7.72 (m, 2H), 7.57 – 7.51 (m, 2H), 7.33 – 7.29 (m, 1H), 6.93 (ddd, *J* = 8.3, 2.7, 1.0 Hz, 1H), 6.80 – 6.71 (m, 2H), 5.99 (s, 1H), 3.97 (dd, *J* = 9.1, 2.2 Hz, 1H), 3.82 (ddd, *J* = 13.5, 2.4, 1.4 Hz, 1H), 3.78 (s, 3H), 3.06 (dd, *J* = 13.6, 9.1 Hz, 1H), 2.46 (s, 3H), 1.82 (d, *J*




δ = 1.1 Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO-*d*₆) δ 160.2 (C), 145.1 (C), 141.4 (C), 139.5 (C), 133.8 (C), 131.0 (CH x 2), 130.6 (CH), 128.3 (CH x 2), 119.1 (CH), 114.8 (CH), 112.6 (CH), 100.7 (CH), 74.0 (CH), 56.0 (CH₂), 49.0 (CH₃), 22.0 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₉H₂₂NSO₄]⁺: 360.1264, found: 360.1264. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 12 min, t_{minor} = 16 min).

3o: (*R*)-2-([1,1'-biphenyl]-4-yl)-6-methyl-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (76.6 mg, 63% yield, 94% ee). R_f = 0.3 (PE/TBME 4/1). [α]_D²⁵ = + 151 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.68 (d, *J* = 8.1 Hz, 4H), 7.56 – 7.49 (m, 4H), 7.41 (t, *J* = 7.3 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 6.03 (t, *J* = 1.2 Hz, 1H), 4.14 (dd, *J* = 9.1, 2.3 Hz, 1H), 3.89 (d, *J* = 13.6 Hz, 1H), 3.12 (dd, *J* = 13.5, 9.1 Hz, 1H), 2.45 (s, 3H), 1.84 (s, 3H), 1.47 – 0.94 (m, 1H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO-*d*₆) δ 145.0 (C), 141.2 (C), 140.5 (C), 137.1 (C), 133.9 (C), 131.0 (CH x 2), 129.8 (CH x 2), 128.5 (CH), 128.2 (CH x 2), 127.7 (CH x 2), 127.6 (CH x 2), 127.6 (CH x 2), 100.6 (CH), 73.9 (CH), 48.8 (CH₂), 21.9 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₂₄H₂₄NSO₃]⁺: 406.1471, found: 406.1470. HPLC (Daicel Chiralcel® column OD-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 13 min, t_{minor} = 18 min).


3p: (*R*)-6-Methyl-2-(naphthalen-2-yl)-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (79.7 mg, 70% yield, 96% ee). R_f = 0.3 (PE/TBME 5/1). [α]_D²⁵ = + 34 (c = 0.1, CHCl₃) ; ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.95 (dd, *J* = 6.5, 3.1 Hz, 3H), 7.78 (d, *J* = 8.2 Hz, 3H), 7.59 – 7.55 (m, 2H), 7.52 (d, *J* = 8.1 Hz, 2H), 7.37 (dd, *J* = 8.6, 1.8 Hz, 1H), 6.05 (s, 1H), 4.29 (dd, *J* = 9.0, 2.3 Hz, 1H), 3.96 (d, *J* = 13.4 Hz, 1H), 3.16 (dd, *J* = 13.6, 9.0 Hz, 1H), 2.45 (s, 3H), 1.87 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO-*d*₆) δ 145.0 (C), 141.2 (C), 135.5 (C), 134.0 (C), 133.7 (C), 133.5 (C), 130.9 (CH x 2), 129.1 (CH x 2), 128.9 (CH x 2), 128.4 (CH x 2), 128.2 (CH x 2), 127.3 (CH), 125.9 (CH), 124.7 (CH), 100.7 (CH), 74.2 (CH), 48.9 (CH₂), 21.9 (CH₃), 18.3 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₂₂H₂₂NSO₃]⁺: 380.1315, found: 380.1315. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 29 min, t_{minor} = 52 min).

3q: (*S*)-6-methyl-2-(thiophen-2-yl)-4-tosyl-3,4-dihydro-2*H*-1,4-oxazine. A colorless oil (73.5 mg, 73% yield, 96% ee). R_f = 0.3 (PE/TBME 5/1). [α]_D²⁵ = + 83 (c = 0.1, CHCl₃); ^1H NMR (400 MHz, CDCl₃) δ 7.68 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 7.9 Hz, 2H), 7.29 (d, *J* = 5.0 Hz, 1H), 6.97 (t, *J* = 4.3 Hz, 1H), 6.88 (d, *J* = 3.3 Hz, 1H), 5.93 (s, 1H), 4.32 (dd, *J* = 9.4, 2.2 Hz, 1H), 3.97 (d, *J* = 13.6 Hz, 1H), 3.12 (q, *J* = 13.5, 9.3 Hz, 1H), 2.45 (s, 3H), 1.81 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl₃) δ 144.5 (C), 141.0 (C), 140.0 (C), 134.0 (C), 130.3 (CH x 2), 127.8 (CH x 2), 127.2 (CH), 126.3 (CH), 125.3 (CH), 100.4 (C), 70.5 (CH), 49.0 (CH₂), 22.0 (CH₃), 18.1 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₆H₁₈NS₂O₃]⁺: 336.0723, found: 336.0723. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 14 min, t_{minor} = 17 min).


3r: (*R*)-4-((4-fluorophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2H-1,4-oxazine. A

 colorless oil (63.0 mg, 63% yield, 94% ee). $R_f = 0.3$ (PE/TBME 5/1). $[\alpha]_D^{25} = +27$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.90 – 7.68 (m, 2H), 7.30 (q, $J = 5.3$, 4.8 Hz, 3H), 7.23 (t, $J = 8.0$ Hz, 2H), 7.14 – 7.03 (m, 2H), 5.90 (s, 1H), 4.04 (dd, $J = 9.6$, 2.2 Hz, 1H), 3.86 (d, $J = 13.6$ Hz, 1H), 2.96 – 2.89 (m, 1H), 1.81 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 165.7 (C, d, $J = 255.9$ Hz), 141.7 (C), 137.3 (C), 133.2 (C, d, $J = 3.1$ Hz), 130.5 (CH x 2, d, $J = 9.2$ Hz), 129.1 (CH x 2), 129.0 (CH), 126.3 (CH x 2), 116.9 (CH x 2, d, $J = 22.6$ Hz), 99.9 (CH), 74.3 (CH), 49.2 (CH₂), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₇H₁₇NSFO₃]⁺: 334.0908, found: 334.0908. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 20 min, t_{minor} = 29 min). HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 20 min, t_{minor} = 29 min).


3s: (*R*)-4-((4-chlorophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2H-1,4-oxazine. A

 colorless oil (73.5 mg, 70% yield, 94% ee). $R_f = 0.3$ (PE/TBME 5/1). $[\alpha]_D^{25} = -26$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.73 (m, 2H), 7.57 – 7.53 (m, 2H), 7.38 – 7.32 (m, 3H), 7.14 (dd, $J = 7.6$, 1.9 Hz, 2H), 5.94 (s, 1H), 4.12 (dd, $J = 9.5$, 2.3 Hz, 1H), 3.93 – 3.88 (m, 1H), 3.01 – 2.94 (m, 1H), 1.85 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.8 (C), 140.0 (C), 137.3 (C), 135.6 (C), 129.9 (CH x 2), 129.2 (CH x 2), 129.1 (CH x 2), 129.0 (CH), 126.3 (CH x 2), 99.8 (C), 74.3 (CH), 49.2 (CH₂), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₇H₁₇NSClO₃]⁺: 350.0612, found: 350.0612. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 18 min, t_{minor} = 26 min). HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 18 min, t_{minor} = 26 min).

3t: (*R*)-4-((4-bromophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2H-1,4-oxazine. A


 colorless oil (88.7 mg, 75% yield, 95% ee). $R_f = 0.3$ (PE/TBME 5/1). $[\alpha]_D^{25} = +24$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 7.74 – 7.70 (m, 2H), 7.69 – 7.65 (m, 2H), 7.38 – 7.31 (m, 3H), 7.15 (dd, $J = 7.5$, 1.9 Hz, 2H), 5.93 (s, 1H), 4.13 (dd, $J = 9.5$, 2.3 Hz, 1H), 3.93 – 3.88 (m, 1H), 2.97 (q, $J = 13.6$, 9.5 Hz, 1H), 1.85 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.7 (C), 137.3 (C), 136.1 (C), 132.9 (CH x 2), 129.3 (CH x 2), 129.1 (CH x 2), 129.0 (CH), 128.5 (C), 126.3 (CH x 2), 99.8 (C), 74.3 (CH), 49.1 (CH₂), 18.2 (CH₃). HRMS (ESI) m/z [M+H]⁺ calculated for [C₁₇H₁₇NSBrO₃]⁺: 394.0107, found: 394.0107. HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 20 min, t_{minor} = 32 min). HPLC (Daicel Chiralcel® column OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 21 min, t_{minor} = 32 min).

3u: (*R*)-6-methyl-4-((4-nitrophenyl)sulfonyl)-2-phenyl-3,4-dihydro-2H-1,4-oxazine. A

 colorless oil (66.0 mg, 61% yield, 96% ee). $R_f = 0.3$ (PE/TBME 3/1). $[\alpha]_D^{25} = +8$ ($c = 0.1$, CHCl₃) ; ¹H NMR (400 MHz, CDCl₃) δ 8.40 (m, 2H), 7.97 (m, 2H), 7.40 – 7.29 (m, 3H), 7.17 – 7.10 (m, 2H), 5.96 (s, 1H), 4.22 (dd, $J = 9.4$, 2.3 Hz, 1H), 3.98 – 3.92 (m, 1H), 3.03 (dd, $J = 13.4$, 9.3 Hz, 1H), 1.86 (s,

3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 150.6 (C), 142.9 (C), 142.2 (C), 137.0 (C), 129.2 (CH), 129.1 (CH x 2), 128.9 (CH x 2), 126.2 (CH x 2), 124.8 (CH x 2), 99.3 (C), 74.6 (CH), 49.1 (CH_2), 18.3 (CH_3). HRMS (ESI) m/z [M+H] $^+$ calculated for $[\text{C}_{17}\text{H}_{17}\text{SN}_2\text{O}_5]^+$: 361.0853, found: 361.0853. HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 34$ min, $t_{\text{minor}} = 43$ min). HPLC (Daicel Chiralcel® column OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 34$ min, $t_{\text{minor}} = 43$ min).

4: (2*S*,6*R*)-4-((4-bromophenyl)sulfonyl)-2-methyl-6-phenylmorpholin-2-ol. A white solid (1.1 g, 91% yield, 98% *ee*, 96/4 *dr*). $R_f = 0.3$ (PE/TBME 3/1). $[\alpha]_D^{25} = -76.7$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.6$ Hz, 2H), 7.60 (d, $J = 8.6$ Hz, 2H), 7.36 – 7.29 (m, 5H), 5.13 (dd, $J = 10.8, 2.8$ Hz, 1H), 3.80 (dt, $J = 11.6, 2.2$ Hz, 1H), 3.72 (dd, $J = 11.4, 1.5$ Hz, 1H), 2.40 (d, $J = 11.4$ Hz, 1H), 2.22 (t, $J = 11.2$ Hz, 1H), 1.49 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 138.0 (C), 134.6 (C), 132.6 (CH), 129.22 (CH), 128.6 (CH), 128.4 (CH), 126.3 (CH), 93.7 (C), 70.5 (CH), 53.1 (CH_2), 51.3 (CH_2), 26.4 (CH_3). HRMS (ESI) m/z [M+Na] $^+$ calculated for $[\text{C}_{17}\text{H}_{18}\text{BrNO}_4\text{SNa}]^+$: 434.0032, found: 434.0032. HPLC (Daicel Chiralcel® column IC-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 25$ min, $t_{\text{minor}} = 29$ min).




6. Single crystal X-ray structure of 4 (CCDC: 2016445)

Identification code	2016445
Empirical formula	C ₁₇ H ₁₈ BrNO ₄ S
Formula weight	412.29
Temperature/K	293.44
Crystal system	Monoclinic
Space group	P2 ₁
a/Å	12.101(3)
b/Å	5.7244(15)
c/Å	14.736(4)
α/°	90
β/°	107.005(7)
γ/°	90
Volume/Å ³	976.1(4)
Z	2
Density (calculated) (g/cm ³)	1.403
Absorption coefficient (mm ⁻¹)	2.231
F(000)	420
Crystal size/mm ³	0.17 x 0.08 x 0.05
Radiation	Mo K\ (\lambda = 0.71073)
2θ range for data collection/°	5.168 to 55.13
Index ranges	-15≤h≤15, -7≤k≤7, -18≤l≤19
Reflections collected	11811
Independent reflections	4493 [R _{int} = 0.0589, R _{sigma} = 0.1101]
Completeness	99%
Refinement method	Full-matrix least-squares on F2
Data/restraints/parameters	4493 / 1/ 218
Goodness-of-fit on F ²	0.811
Final R indexes [I>=2σ(I)]	R ₁ = 0503, wR ₂ = 0.1236
Final R indexes [all data]	R ₁ = 0.1305, wR ₂ = 0.1696
Largest diff. peak/hole / e Å ⁻³	0.21/-0.35
Flack parameter	0.038(10)

5. HPLC Analysis of chiral alkynols (2), chiral products (3), and 4.

(R)-2a: (R)-N-(2-hydroxy-2-phenylethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide.
HPLC (AD-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 44 min, t_{minor} = 52 min).




化合物表视图						
ID#	名称	保留时间	峰#	面积	高度	面积%
1	RT44.708	44.708	1	60313387	458562	49.8893
2	RT52.838	52.838	2	60581063	416595	50.1107




化合物表视图						
ID#	名称	保留时间	峰#	面积	高度	面积%
1	RT44.563	44.563	1	18217431	148445	96.7181
2	RT52.119	52.119	2	236562	2238	1.2819


Translation of Chinese into English as follows.



(R)-2b: (R)-N-(2-(4-fluorophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OJ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 31$ min, $t_{\text{minor}} = 42$ min).




Translation of Chinese into English as follows.




(R)-2c:

(*R*)-*N*-(2-(3-fluorophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, *t*_{major} = 36 min, *t*_{minor} = 41 min).



化合物表视图

ID#	名称	保留时间	峰#	面积	面积%	高度	高度%
1	RT36.077	36.077	1	30959128	50.4061	292975	52.8607
2	RT41.132	41.132	2	30460253	49.5939	261265	47.1393



化合物表视图

ID#	名称	保留时间	峰#	面积	面积%	高度	高度%
1	RT36.219	36.219	1	21168552	98.2649	203498	97.9046
2	RT41.112	41.112	2	373781	1.7351	4355	2.0954


Translation of Chinese into English as follows.

Table view of compound


Name	RetTime [min]	Peak	Area	Area%	Height	Height %
------	---------------	------	------	-------	--------	----------




(R)-2d: (R)-N-(2-(2-fluorophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OZ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 22$ min, $t_{\text{minor}} = 27$ min).



Translation of Chinese into English as follows.



(R)-2e: (R)-N-(2-(4-chlorophenyl)-2-oxoethyl)-4-Methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OD-3, elute: Hexane/i-PrOH = 97/3, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 41$ min, $t_{\text{minor}} = 49$ min).





Translation of Chinese into English as follows.


Table view of compound

	Name	RetTime [min]	Peak	Area	Height	Area%
<input type="checkbox"/> 化合物表视图						
1	RT16.273	16.273	1	29062298	1157361	98.0529
2	RT18.111	18.111	2	577094	24437	1.9471


(R)-2f: (R)-N-(2-(3-chlorophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, $t_{\text{major}} = 43$ min, $t_{\text{minor}} = 50$ min).




Translation of Chinese into English as follows.




(R)-2g: (R)-N-(2-(2-chlorophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OJ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 25 min, t_{minor} = 33 min).




Translation of Chinese into English as follows.



(R)-2h: (R)-N-(2-(4-bromophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OD-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 26$ min, $t_{\text{minor}} = 30$ min).




Translation of Chinese into English as follows.




(R)-2i:

(R)-N-(2-(3-bromophenyl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/i-PrOH = 95/05, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, $t_{\text{major}} = 45$ min, $t_{\text{minor}} = 53$ min).





Translation of Chinese into English as follows.


Table view of compound



(R)-2j: (R)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OD-3, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 21$ min, $t_{\text{minor}} = 26$ min).





Translation of Chinese into English as follows.



(R)-2k:

(*R*)-*N*-(2-(4-cyanophenyl)-2-hydroxyethyl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OD-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, *t*_{major} = 25 min, *t*_{minor} = 30 min).



Translation of Chinese into English as follows.

Table view of

compound

Name

RetTime [min]


Peak

Area


Area%

Height


Height%




(R)-2I: (R)-N-(2-hydroxy-2-(p-tolyl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide.
 HPLC (AD-H, elute: Hexane/i-PrOH = 98/2, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 123 \text{ min}$, $t_{\text{minor}} = 140 \text{ min}$).




Translation of Chinese into English as follows.




(R)-2m: (R)-N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AS-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 42$ min, $t_{\text{minor}} = 46$ min).




Translation of Chinese into English as follows.




(R)-2n: (R)-N-(2-hydroxy-2-(3-methoxyphenyl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC(AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 0.8 mL/min, 25 °C, $t_{\text{major}} = 28 \text{ min}$, $t_{\text{minor}} = 35 \text{ min}$).




Translation of Chinese into English as follows.




(R)-2o: (R)-N-(2-([1,1'-biphenyl]-4-yl)-2-hydroxyethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 31 min, t_{minor} = 37 min).




Translation of Chinese into English as follows.




(R)-2p: (R)-N-(2-hydroxy-2-(naphthalen-2-yl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 34$ min, $t_{\text{minor}} = 40$ min).




Translation of Chinese into English as follows.




(R)-2q: (R)-N-(2-hydroxy-2-(thiophen-2-yl)ethyl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (OB-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 33min, t_{minor} = 45 min).




Translation of Chinese into English as follows.




(R)-2r: (R)-4-Fluoro-N-(2-hydroxy-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide.
 HPLC (AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 20 \text{ min}$, $t_{\text{minor}} = 22 \text{ min}$).




Translation of Chinese into English as follows.




(R)-2s: (*R*)-4-Chloro-*N*-(2-hydroxy-2-phenylethyl)-*N*-(prop-2-yn-1-yl)benzenesulfonamide. HPLC (AD-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, *t*_{major} = 19 min, *t*_{minor} = 22 min).




Translation of Chinese into English as follows.




(R)-2t: (R)-4-Bromo-N-(2-hydroxy-2-phenylethyl)-N-(prop-2-yn-1-yl)benzenesulfonamide.
 HPLC (AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 21 \text{ min}$, $t_{\text{minor}} = 24 \text{ min}$).




Translation of Chinese into English as follows.




(R)-2u: (R)-N-(2-hydroxy-2-phenylethyl)-4-Nitro-N-(prop-2-yn-1-yl)benzenesulfonamide.
 HPLC (AD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 39 \text{ min}$, $t_{\text{minor}} = 43 \text{ min}$).




Translation of Chinese into English as follows.





(R)-3a: (R)-6-Methyl-2-phenyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OJ-H, elute: Hexane/*i*-PrOH=90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 15$ min, $t_{\text{minor}} = 23$ min).




Translation of Chinese into English as follows.




(R)-3b: (R)-2-(4-fluorophenyl)-6-Methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OJ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 16$ min, $t_{\text{minor}} = 26$ min).




Translation of Chinese into English as follows.




(R)-3c: (R)-2-(3-fluorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 12$ min, $t_{\text{minor}} = 17$ min).




Translation of Chinese into English as follows.





(R)-3d: (R)-2-(2-fluorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OJ-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 28 \text{ min}$, $t_{\text{minor}} = 37 \text{ min}$).




Translation of Chinese into English as follows.




(R)-3e: (R)-2-(4-chlorophenyl)-6-Methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 11$ min, $t_{\text{minor}} = 22$ min).




Translation of Chinese into English as follows.





(R)-3f: (R)-2-(3-chlorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 10$ min, $t_{\text{minor}} = 13$ min).



Translation of Chinese into English as follows.




(R)-3g: (R)-2-(2-chlorophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 9 \text{ min}$, $t_{\text{minor}} = 13 \text{ min}$).




Translation of Chinese into English as follows.

Table view of compound	Name	RetTime [min]	Peak	Area	Height	Area%
<input type="checkbox"/> 化合物表视图						
1	RT16.273	16.273	1	29062298	1157381	98.0529
2	RT18.111	18.111	2	577094	24437	1.9471


(R)-3h: (R)-2-(4-bromophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 12$ min, $t_{\text{minor}} = 25$ min).



Translation of Chinese into English as follows.





(R)-3i: (R)-2-(3-bromophenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/i-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 21$ min, $t_{\text{minor}} = 26$ min).



Translation of Chinese into English as follows.

Table view of compound		Name	RetTime [min]	Peak	Area	Height	Area%
<input type="checkbox"/> 化合物表视图							
ID#	名称	保留时间	峰#	面积	高度	面积%	
1	RT16.273	16.273	1	29062298	1157381	98.0529	
2	RT18.111	18.111	2	577094	24437	1.9471	



(R)-3j: (R)-6-Methyl-4-tosyl-2-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-1,4-oxazine.
 HPLC (OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 12 \text{ min}$, $t_{\text{minor}} = 17 \text{ min}$).



Translation of Chinese into English as follows.

Table view of compound		Name	RetTime [min]	Peak	Area	Height	Area%
↑	↑						
<input type="checkbox"/> 化合物表视图							
1	RT16.273	16.273	1	29062298	1157381	98.0529	
2	RT18.111	18.111	2	577094	24437	1.9471	

(R)-3k: (R)-4-(6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazin-2-yl)benzonitrile.HPLC (OD-H , elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 19$ min, $t_{\text{minor}} = 25$ min).





Translation of Chinese into English as follows.


Table view of compound

	Name	RetTime [min]	Peak	Area	Height	Area%
<input type="checkbox"/> 化合物表视图						
1	RT16.273	16.273	1	29062298	1157381	98.0529
2	RT18.111	18.111	2	577094	24437	1.9471


(R)-3l: (R)-6-Methyl-2-(p-tolyl)-4-tosyl-3,4-dihydro-2H-1,4-oxazine.HPLC (OZ-H, elute: Hexane/*i*-PrOH = 95/5, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 17$ min, $t_{\text{minor}} = 25$ min).



Translation of Chinese into English as follows.





(R)-3m: (R)-2-(4-methoxyphenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 14 \text{ min}$, $t_{\text{minor}} = 30 \text{ min}$).




Translation of Chinese into English as follows.





(R)-3n: (R)-2-(3-methoxyphenyl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/*i*-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 12$ min, $t_{\text{minor}} = 16$ min).




Translation of Chinese into English as follows.





(R)-3o: (R)-2-([1,1'-biphenyl]-4-yl)-6-methyl-4-tosyl-3,4-dihydro-2H-1,4-oxazine.HPLC (OD-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 13 \text{ min}$, $t_{\text{minor}} = 18 \text{ min}$).




Translation of Chinese into English as follows.




(R)-3p: (R)-6-Methyl-2-(naphthalen-2-yl)-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OJ-H, elute: Hexane/i-PrOH = 85/15, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 29$ min, $t_{\text{minor}} = 52$ min).




Translation of Chinese into English as follows.




(R)-3q: (R)-6-methyl-2-(thiophen-2-yl)-4-tosyl-3,4-dihydro-2H-1,4-oxazine. HPLC (OZ-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 14$ min, $t_{\text{minor}} = 17$ min).




Translation of Chinese into English as follows.





(R)-3r: (*R*)-4-((4-fluorophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2*H*-1,4-oxazine.
 HPLC (OJ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 20 \text{ min}$, $t_{\text{minor}} = 29 \text{ min}$).




Translation of Chinese into English as follows.





(R)-3s: (R)-4-((4-chlorophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2H-1,4-oxazine.
 HPLC (OJ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 18 \text{ min}$, $t_{\text{minor}} = 26 \text{ min}$).




Translation of Chinese into English as follows.





(R)-3t: (R)-4-((4-bromophenyl)sulfonyl)-6-methyl-2-phenyl-3,4-dihydro-2H-1,4-oxazine.
 HPLC (OJ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C,
 $t_{\text{major}} = 21 \text{ min}$, $t_{\text{minor}} = 32 \text{ min}$).




Translation of Chinese into English as follows.





(R)-3u: (R)-6-methyl-4-((4-nitrophenyl)sulfonyl)-2-phenyl-3,4-dihydro-2H-1,4-oxazine.
 HPLC (OZ-H, elute: Hexane/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, t_{major} = 34 min, t_{minor} = 43 min).




Translation of Chinese into English as follows.



4: (2S,6R)-4-((4-bromophenyl)sulfonyl)-2-methyl-6-phenylmorpholin-2-ol. HPLC (IC-H, elute: Hexane/i-PrOH = 90/10, detector: 254 nm, flow rate: 1.0 mL/min, 25 °C, $t_{\text{major}} = 25$ min, $t_{\text{minor}} = 29$ min).




Translation of Chinese into English as follows.




7. The ^1H -NMR and ^{13}C -NMR of compounds (1-2), chiral products (3), and 4.


¹H-NMR and ¹³C-NMR spectra of 1a.




¹H-NMR and ¹³C-NMR spectra of 1b.




¹H-NMR and ¹³C-NMR spectra of 1c.




¹H-NMR and ¹³C-NMR spectra of 1d.





¹H-NMR and ¹³C-NMR spectra of 1e.




¹H-NMR and ¹³C-NMR spectra of 1f.




¹H-NMR and ¹³C-NMR spectra of 1g.





¹H-NMR and ¹³C-NMR spectra of 1h.




¹H-NMR and ¹³C-NMR spectra of 1i.




¹H-NMR and ¹³C-NMR spectra of 1j.




¹H-NMR and ¹³C-NMR spectra of 1k.




¹H-NMR and ¹³C-NMR spectra of 1l.




¹H-NMR and ¹³C-NMR spectra of 1m.




¹H-NMR and ¹³C-NMR spectra of 1n.




¹H-NMR and ¹³C-NMR spectra of 1o.




¹H-NMR and ¹³C-NMR spectra of 1p.




¹H-NMR and ¹³C-NMR spectra of 1q.




¹H-NMR and ¹³C-NMR spectra of 1r.




¹H-NMR and ¹³C-NMR spectra of 1s.




¹H-NMR and ¹³C-NMR spectra of 1t.




¹H-NMR and ¹³C-NMR spectra of 1u.




¹H-NMR and ¹³C-NMR spectra of (R)-2a.




¹H-NMR and ¹³C-NMR spectra of (R)-2b.




¹H-NMR and ¹³C-NMR spectra of (R)-2c.




¹H-NMR and ¹³C-NMR spectra of (R)-2d.




¹H-NMR and ¹³C-NMR spectra of (R)-2e.




¹H-NMR and ¹³C-NMR spectra of (R)-2f.




¹H-NMR and ¹³C-NMR spectra of (R)-2g.




¹H-NMR and ¹³C-NMR spectra of (R)-2h.




¹H-NMR and ¹³C-NMR spectra of (R)-2i.




¹H-NMR and ¹³C-NMR spectra of (R)-2j.




¹H-NMR and ¹³C-NMR spectra of (*R*)-2k.




¹H-NMR and ¹³C-NMR spectra of (R)-2l.




¹H-NMR and ¹³C-NMR spectra of (R)-2m.




¹H-NMR and ¹³C-NMR spectra of (R)-2n.




¹H-NMR and ¹³C-NMR spectra of (R)-2o.




¹H-NMR and ¹³C-NMR spectra of (R)-2p.




¹H-NMR and ¹³C-NMR spectra of (*R*)-2q.




¹H-NMR and ¹³C-NMR spectra of (R)-2r.




¹H-NMR and ¹³C-NMR spectra of (R)-2s.




¹H-NMR and ¹³C-NMR spectra of (R)-2t.




¹H-NMR and ¹³C-NMR spectra of (R)-2u.




¹H-NMR and ¹³C-NMR spectra of (R)-3a.




¹H-NMR and ¹³C-NMR spectra of (R)-3b.




¹H-NMR and ¹³C-NMR spectra of (R)-3c.




¹H-NMR and ¹³C-NMR spectra of (R)-3d.




¹H-NMR and ¹³C-NMR spectra of (R)-3e.




¹H-NMR and ¹³C-NMR spectra of (R)-3f.




¹H-NMR and ¹³C-NMR spectra of (R)-3g.




¹H-NMR and ¹³C-NMR spectra of (R)-3h.





¹H-NMR and ¹³C-NMR spectra of (R)-3i.




¹H-NMR and ¹³C-NMR spectra of (R)-3j.




¹H-NMR and ¹³C-NMR spectra of (R)-3k.




¹H-NMR and ¹³C-NMR spectra of (R)-3l.




¹H-NMR and ¹³C-NMR spectra of (R)-3m.





¹H-NMR and ¹³C-NMR spectra of (R)-3n.




¹H-NMR and ¹³C-NMR spectra of (R)-3o.




¹H-NMR and ¹³C-NMR spectra of (R)-3p.




¹H-NMR and ¹³C-NMR spectra of (R)-3q.




¹H-NMR and ¹³C-NMR spectra of (R)-3r.




¹H-NMR and ¹³C-NMR spectra of (R)-3s.



¹H-NMR and ¹³C-NMR spectra of (R)-3t.



¹H-NMR and ¹³C-NMR spectra of (R)-3u.



4: (2*S*,6*R*)-4-((4-bromophenyl)sulfonyl)-2-methyl-6-phenylmorpholin-2-ol.

